Entera Bio’s (ENTX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Entera Bio (NASDAQ:ENTX) in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the stock.

Entera Bio Stock Performance

Shares of ENTX opened at $1.95 on Tuesday. The company has a market cap of $69.78 million, a price-to-earnings ratio of -7.50 and a beta of 1.62. Entera Bio has a 1-year low of $1.30 and a 1-year high of $3.35. The company’s fifty day simple moving average is $2.21 and its 200 day simple moving average is $2.02.

Hedge Funds Weigh In On Entera Bio

A number of institutional investors have recently added to or reduced their stakes in ENTX. Parkman Healthcare Partners LLC increased its holdings in shares of Entera Bio by 2.4% in the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock valued at $781,000 after purchasing an additional 9,558 shares during the last quarter. Perigon Wealth Management LLC acquired a new position in shares of Entera Bio in the fourth quarter valued at $325,000. Northern Trust Corp acquired a new position in shares of Entera Bio in the fourth quarter valued at $450,000. Finally, Knoll Capital Management LLC increased its holdings in shares of Entera Bio by 51.5% in the fourth quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company’s stock valued at $12,470,000 after purchasing an additional 2,000,000 shares during the last quarter. 14.11% of the stock is currently owned by institutional investors and hedge funds.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.